Tango Therapeutics Announces Executive Chair Transition
Dr. Barbara Weber, Executive Chairman of Tango Therapeutics (NASDAQ: TNGX), is stepping down to pursue other interests. The clinical-stage biotechnology company, which focuses on precision cancer medicines using synthetic lethality principles, expressed gratitude for Weber's leadership and vision while affirming confidence in the company's future direction under President Dr. Malte Peters.